ARWR logo

Arrowhead Research Corporation

ARWR

ARWR: Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

more

Show ARWR Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of ARWR by members of U.S. Congress

Politician Type Traded
Daniel Goldman House / D Sale $1,001 - $15,000 Jan. 31, 2023
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ARWR's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use Apr. 18, 2023
  • Patent Title: Integrin ligands and uses thereof Mar. 07, 2023
  • Patent Title: Rnai agents for hepatitis b virus infection Feb. 28, 2023
  • Patent Title: Rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use Jan. 10, 2023
  • Patent Title: Rnai therapy for hepatitis b virus infection Dec. 27, 2022
  • Patent Title: Rnai agents for hepatitis b virus infection Dec. 06, 2022
  • Patent Title: Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin Jul. 12, 2022
  • Patent Title: Organic compositions to treat epas1-related diseases Mar. 01, 2022
  • Patent Title: Rnai agents for inhibiting expression of alpha-enac and methods of use Jan. 04, 2022
  • Patent Title: Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) Jan. 04, 2022
  • Patent Title: Rnai inhibition of alpha-enac expression Dec. 28, 2021
  • Patent Title: Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use Dec. 21, 2021
  • Patent Title: Alpha-v beta-6 integrin ligands and uses thereof Nov. 23, 2021
  • Patent Title: Targeting ligands Nov. 16, 2021
  • Patent Title: Organic compositions to treat hsf1-related diseases Aug. 17, 2021
  • Patent Title: 5′-cyclo-phosphonate modified nucleotides Aug. 03, 2021
  • Patent Title: Organic compositions to treat apoc3-related diseases Jul. 20, 2021
  • Patent Title: Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use May. 04, 2021
  • Patent Title: Compositions and methods for inhibiting gene expression of hif2alpha Feb. 23, 2021
  • Patent Title: Compositions and methods for inhibiting gene expression of factor xii Dec. 08, 2020
  • Patent Title: Compositions and methods for inhibiting gene expression of hepatitis b virus Dec. 08, 2020
  • Patent Title: Rnai therapy for hepatitis b virus infection Oct. 20, 2020
  • Patent Title: Rnai agents for hepatitis b virus infection Sep. 22, 2020
  • Patent Title: Compositions and methods for inhibiting gene expression of lpa May. 26, 2020
  • Patent Title: Rnai agents for inhibiting expression of alpha-enac and methods of use Mar. 17, 2020
  • Patent Title: Organic compositions to treat beta-enac-related diseases Feb. 04, 2020
  • Patent Title: Rnai inhibition of alpha-enac expression Jan. 28, 2020
  • Patent Title: Organic compositions to treat epas1-related diseases Jan. 21, 2020
  • Patent Title: Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use Oct. 22, 2019
  • Patent Title: Organic compositions to treat hsf1-related diseases Jun. 25, 2019
  • Patent Title: Compositions for targeted delivery of sirna Jun. 11, 2019
  • Patent Title: Compositions and methods for inhibiting gene expression of factor xii Jun. 04, 2019
  • Patent Title: Targeting ligands May. 21, 2019
  • Patent Title: Organic compositions to treat hsf1-related diseases May. 14, 2019
  • Patent Title: Dsrna for treating viral infection Apr. 30, 2019
  • Patent Title: Targeting ligands for therapeutic compounds Apr. 02, 2019
  • Patent Title: Organic compositions to treat apoc3-related diseases Mar. 26, 2019
  • Patent Title: Transferrin/transferrin receptor-mediated sirna delivery Nov. 27, 2018
  • Patent Title: Rnai therapy for hepatitis b virus infection Nov. 20, 2018
  • Patent Title: Organic compositions to treat beta-enac-related diseases Sep. 25, 2018
  • Patent Title: Disubstituted maleic anhydrides with altered kinetics of ring closure Aug. 28, 2018
  • Patent Title: Disulfide-containing alkyne linking agents Aug. 14, 2018
  • Patent Title: Organic compositions to treat beta-catenin-related diseases Jul. 17, 2018
  • Patent Title: Reversibly masked polymers Jul. 17, 2018
  • Patent Title: Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin Jun. 26, 2018
  • Patent Title: Biologically cleavable tetrapeptide linking agents Jun. 26, 2018
  • Patent Title: Compositions and methods for inhibiting gene expression of hif2alpha May. 22, 2018
  • Patent Title: Compositions and methods for inhibiting expression of rrm2 genes Apr. 10, 2018
  • Patent Title: Compositions and methods for inhibiting gene expression of lpa Apr. 03, 2018
  • Patent Title: Interfering rna delivery system and uses thereof Apr. 03, 2018
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of ARWR in WallStreetBets Daily Discussion

ARWR News

Recent insights relating to ARWR

CNBC Recommendations

Recent picks made for ARWR stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ARWR

Corporate Flights

Flights by private jets registered to ARWR